TNFSF10 and neoplasm: The introduction of a diabody configuration based on the humanized variable regions of Cetuximab (DbαEGFR-scTRAIL) resulted in an even higher bioactivity of recombinant TRAIL both in vitro and in vivo, as seen by the strong reduction of tumor size and prolonged survival of nude mice carrying Colo205 xenografts [15].